LSC - 2021 - Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
R. Saša, M. Janic (mjanic@gmail.com / Department for endocrinology, d. and metabolic diseases, U. Medical Centre,Ljubljana), M. Lunder (mojca.lunder@kclj.si / Department for endocrinology, d. and metabolic diseases, U. Medical Centre,Ljubljana), M. Šabovic (miso.sabovic@kclj.si / Department of vascular diseases, U. Medical Centre,Ljubljana), B. Salobir (barbara.salobir.pulmo@kclj.si / Department of pulmonology, U. Medical Centre,Ljubljana)
Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Saša, M. Janic (mjanic@gmail.com / Department for endocrinology, d. and metabolic diseases, U. Medical Centre,Ljubljana), M. Lunder (mojca.lunder@kclj.si / Department for endocrinology, d. and metabolic diseases, U. Medical Centre,Ljubljana), M. Šabovic (miso.sabovic@kclj.si / Department of vascular diseases, U. Medical Centre,Ljubljana), B. Salobir (barbara.salobir.pulmo@kclj.si / Department of pulmonology, U. Medical Centre,Ljubljana). LSC - 2021 - Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis. 2104
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: